Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8+ T cells with detection by ELISPOT and HLA-multimer staining
暂无分享,去创建一个
S. H. van der Burg | M. Welters | P. Romero | C. Ottensmeier | C. Britten | C. Gouttefangeas | A. Cazaly | D. Maurer | S. Walter | C. Jandus | K. McCann | Nicole Bidmon | Karoline Laske | L. Chudley | A. Coleman | H. Schröder | Linda F. M. Stynenbosch | Katy J McCann | Angelica M. Cazaly
[1] F. Baldanti,et al. Enumeration and Characterization of Human Memory T Cells by Enzyme-Linked Immunospot Assays , 2013, Clinical & developmental immunology.
[2] F. Baldanti,et al. Detection of Epstein–Barr virus‐specific memory CD4+ T cells using a peptide‐based cultured enzyme‐linked immunospot assay , 2013, Immunology.
[3] S. H. van der Burg,et al. Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols , 2012, Cancer Immunology, Immunotherapy.
[4] H. Rammensee,et al. Promiscuous survivin peptide induces robust CD4+ T‐cell responses in the majority of vaccinated cancer patients , 2012, International journal of cancer.
[5] D. Dearnaley,et al. DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8+ T-cell responses and increases PSA doubling time , 2012, Cancer Immunology, Immunotherapy.
[6] Steven A. Rosenberg,et al. Adoptive immunotherapy for cancer: harnessing the T cell response , 2012, Nature Reviews Immunology.
[7] C. Gouttefangeas,et al. Serum is not required for ex vivo IFN-γ ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program , 2010, Cancer Immunology, Immunotherapy.
[8] Tom H. M. Ottenhoff,et al. Identification of Major Factors Influencing ELISpot-Based Monitoring of Cellular Responses to Antigens from Mycobacterium tuberculosis , 2009, PloS one.
[9] S. H. van der Burg,et al. Performance of serum-supplemented and serum-free media in IFNγ Elispot Assays for human T cells , 2009, Cancer Immunology, Immunotherapy.
[10] Sylvia Janetzki,et al. "MIATA"-minimal information about T cell assays. , 2009, Immunity.
[11] P. Klenerman,et al. The relationship between human effector and memory T cells measured by ex vivo and cultured ELISPOT following recent and distal priming , 2009, Immunology.
[12] L. Ben-Porat,et al. Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium , 2009, Cancer Immunology, Immunotherapy.
[13] Ferdousi Chowdhury,et al. Fit for purpose? A case study: validation of immunological endpoint assays for the detection of cellular and humoral responses to anti-tumour DNA fusion vaccines , 2009, Cancer Immunology, Immunotherapy.
[14] P. Kaleebu,et al. Concordant Proficiency in Measurement of T-Cell Immunity in Human Immunodeficiency Virus Vaccine Clinical Trials by Peripheral Blood Mononuclear Cell and Enzyme-Linked Immunospot Assays in Laboratories from Three Continents , 2008, Clinical and Vaccine Immunology.
[15] J. Lisziewicz,et al. HIV-1-Specific T Cell Precursors with High Proliferative Capacity Correlate with Low Viremia and High CD4 Counts in Untreated Individuals1 , 2008, The Journal of Immunology.
[16] A. Mackensen,et al. The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays , 2007, Cancer Immunology, Immunotherapy.
[17] Sylvia Janetzki,et al. Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI) , 2007, Cancer Immunology, Immunotherapy.
[18] Guido Ferrari,et al. Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. , 2005, AIDS research and human retroviruses.
[19] M. Plebanski,et al. Cellular immunity induced by the recombinant Plasmodium falciparum malaria vaccine, RTS,S/AS02, in semi‐immune adults in The Gambia , 2004, Clinical and experimental immunology.
[20] P. Ott,et al. Comparison of cytokine ELISpot assay formats for the detection of islet antigen autoreactive T cells. Report of the third immunology of diabetes society T-cell workshop. , 2003, Journal of autoimmunity.
[21] Rustom Antia,et al. Lineage relationship and protective immunity of memory CD8 T cell subsets , 2003, Nature Immunology.
[22] M. Hudgens,et al. Moving to human immunodeficiency virus type 1 vaccine efficacy trials: defining T cell responses as potential correlates of immunity. , 2003, The Journal of infectious diseases.
[23] H. Thomas,et al. Evolution of Epitope-Specific Memory CD4+ T Cells After Clearance of Hepatitis C Virus , 2002, The Journal of Immunology.
[24] A. Eggermont,et al. Quantitation of antigen-reactive T cells in peripheral blood by IFNgamma-ELISPOT assay and chromium-release assay: a four-centre comparative trial. , 2000, Journal of immunological methods.